<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 · Science · 4,427 citations
https://doi.org/10.1126/science.1141478
J
Jeffrey A. Engelman
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
874
Papers
85.1K
Citations
131
h-index
225
i10-index
Jeffrey A. Engelman is an academic researcher from Selecta Biosciences (United States). The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Melanoma and MAPK Pathways & Colorectal Cancer Treatments and Studies. The author has an h-index of 131, co-authored 743 publications.
ORCID: 0009-0004-0775-4523Papers by this author
worksGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
2011 · Science Translational Medicine · 3,511 citations
https://doi.org/10.1126/scitranslmed.3002003
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
2006 · Nature Reviews Genetics · 3,280 citations
https://doi.org/10.1038/nrg1879
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 · Nature reviews. Cancer · 2,427 citations
https://doi.org/10.1038/nrc2664
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
2017 · Nature · 1,912 citations
https://doi.org/10.1038/nature23007
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
2016 · Nature Communications · 1,522 citations
https://doi.org/10.1038/ncomms10501
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat